CHU d'Estaing

Clermont-Ferrand 11 trials 7 recruiting

11 Registered trials

7 Currently recruiting

Organisation

CHU d'Estaing

Location

Clermont-Ferrand, France

Identifier

ORL-000008004

Address

1 place Lucie et Raymond Aubrax, 63100, France

Departments

digestive chirurgy
Digestive oncology
Hématologie
Hématologie Clinique
Hématologie clinique et thérapie cellulaire
Hematology
Oncologie
Oncologie digestive
oncology
Pediatric oncology department

Clinical trials at this site (11)

Search interface

Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplas… Pending

2024-515362-13-00 Philadelphia-negative myeloproliferative neoplasms are 10
CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) P… Pending

2024-516328-32-00 CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) 4
Dose dense re-challenge of high dose methotrexate (hd-mtx) with glucarpidase (cpg2) for relapsed primary cns lymphoma (pcnsl): A phase 1 tri… Recruiting

2024-511900-17-00 Oncology: RELAPSED PRIMARY CNS LYMPHOMA 3 2025-02-14
Open label phase II study evaluating the efficacy and safety of the combination of tagraxofusp and venetoclax in treatment-naive blastic pla… Recruiting

2024-511003-42-00 BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASMS 4 2025-12-11
HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t… Recruiting

2024-514917-36-00 Patients with High Risk Neuroblastoma 5 2024-11-21
FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting

2024-515300-39-00 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE 4 2024-10-18
PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or ge… Recruiting

2024-511070-68-01 Ampullary adenocarcinoma 5 2024-09-24
Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5- fluorouracile ± nivolumab in frail patients with advanced, recurren… Recruiting

2024-512999-35-00 Patients with HER 2 negative locally advanced, recurren 4 2023-06-23
FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Recruiting

2024-510579-40-00 Rhabdoyosarcoma 9 2020-10-07
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient… Ended

2024-518741-21-00 colon cancer 4 2014-12-23
Prospective and multicentre evaluation of 3 different doses of IV busulfan associated with fludarabine and thymoglobuline in the conditionin… Ended

2024-516435-27-00 High-risk myeloïd malignancies 4 2024-11-05